We provide the means and opportunity to test promising new compounds and therapeutic strategies simultaneously in Asian and Caucasian patients with cancer.
We study pharmacogenomics in relation to ethnicity.
We develop better therapies for cancers common in Asia and the Pacific.
We provide high quality, credible and reliable data through ICH-GCP compliant clinical trials for rapid registration and licensing of new compounds in Asia.